ArticleMedicine2025
Scutellarein attenuates alcohol-induced hepatocyte injury by modulating NF-κB and NRF2 signaling pathways.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultra-Micro Powder From Edible Plants (Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlcohol-induced liver injury remains a major public health concern, and effective hepatoprotective agents are urgently needed. Scutellarein (SCU), a natural flavonoid, has shown potential biological activity, but its hepatoprotective effects and underlying mechanisms against alcohol-induced hepatocyte injury have not been fully elucidated.
methodsAn in vitro model of alcohol-induced hepatocyte injury was established using human LO2 cells exposed to 400 mM alcohol. Cells were pretreated with 5 µM SCU, and multiple assays were performed to evaluate hepatocyte viability, hepatic enzyme activity, apoptosis, inflammatory cytokine expression, oxidative stress, and related signaling pathways.
resultsSCU pretreatment effectively reversed the alcohol-induced reduction in cell viability and significantly lowered alanine aminotransferase and aspartate aminotransferase levels. SCU inhibited apoptosis by downregulating BAX and upregulating BCL2, and attenuated inflammatory responses by reducing interleukin-1β, interleukin-6, and tumor necrosis factor-alpha expression. Mechanistically, SCU suppressed nuclear factor kappa-B signaling by decreasing phosphorylation of p65 and inhibitor of nuclear factor kappa-Bα. In addition, SCU enhanced antioxidant defense by upregulating superoxide dismutase 1, superoxide dismutase 2, and catalase, and activating the nuclear factor erythroid 2-related factor 2-NAD(P)H quinone dehydrogenase 1 pathway.
conclusionSCU protects hepatocytes against alcohol-induced injury by modulating apoptosis, inflammation, and oxidative stress through regulation of nuclear factor kappa-B and nuclear factor erythroid 2-related factor 2 signaling pathways. These findings highlight its potential as a promising hepatoprotective agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.